Compare Pfizer Inc (PFE) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs T Rowe Price Group Inc — how do they compare? Pfizer Inc trades at $28.07 (market cap $158.56B), while T Rowe Price Group Inc trades at $105.55 (market cap $22.23B). The key difference: Pfizer Inc is far larger — about 7.1× T Rowe Price Group Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and T Rowe Price Group Inc for 115 Days on average.
| PFE | TROW | |
|---|---|---|
Market Cap | $158.56B | $22.23B |
Volume | 44,138,282 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $29.02 | $121.68 |
52-Week Low | $23.67 | $86.19 |
Typical Hold Time | 158 Days | 115 Days |
Enterprise Value | $210.06B | $19.43B |
Dividend Yield | 6.18% | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
T. Rowe Price Group (TROW) trades at $104.07, showing modest daily gains of 0.45%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a low P/E of 10.46 and robust profitability metrics. Recent earnings show two consecutive beats, with Q3 2026 results pending. The company maintains solid cash flow generation and recently announced a $1.30 dividend payment for September 2026, continuing its 40-year dividend growth streak.
TROW offers value characteristics with attractive valuation multiples and consistent dividend growth, though technical weakness and mixed analyst sentiment suggest near-term caution. Upside potential exists to the $112 consensus target, but investors face risks from market-sensitive revenue streams and ongoing net outflows despite AUM growth to $1.90 trillion as of August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
